rather than diagnoses 6, 25 and the high degree of concordance among the neuroanatomical profiles of both schizophrenia and BD-I, 26, 27 we set out to determine the neuroanatomical profile of subgroups of patients with either schizophrenia or BD-I, defined instead on the basis of working memory performance using a well-characterized working memory task (n-back). 28 Prior efforts to distinguish neuroanatomical underpinnings of schizophrenia and BD-I have implicated a range of overlapping brain regions. Both disorders have been associated with volume deficits of the frontal lobes, particularly precentral, inferior frontal, orbitofrontal and anterior cingulate gyri, and the insula. [9] [10] [11] [12] In addition to frontal lobe deficits, bipolar disorder has been uniquely associated with enlarged amygdala volume. [29] [30] [31] Typically, schizophrenia is characterized by a larger magnitude and broader range of volume reductions, 10, 29, 30 with grey matter volume deficits additionally encompassing superior, inferior and medial temporal lobe gyri, hippocampus/ amygdala and thalamus, in addition to reduced global brain volume and ventricular enlargement. 26, 32 However, this literature is potentially confounded by a myriad of illness-related features (e.g., symptom profile, medication); not surprisingly, the structural imaging literature on both disorders shows high variability with generally poor levels of replication. Nonetheless, the overlap among reported neuroanatomical aberrations suggests that shared regional brain volume loss may underpin phenotypic commonalities (e.g., working memory impairments) among individuals with either disorder.
Previous studies have generally not observed consistent associations between domains of cognitive impairment and neuroanatomical alterations in either disorder. Some evidence suggests that regionally specific brain volumes, particularly prefrontal cortex and subcortical nuclei, may show a linear association with working memory and executive functioning performance in both disorders [33] [34] [35] [36] [37] as well as an association between integrity of frontoparietal white matter tracts and working memory ability in patients with schizophrenia 38 ; however, other evidence suggests more complex associations may exist between neuroanatomy and task-specific domains of cognition. 49, 40 For example, a study found that people with schizophrenia showed a lack of the normal linear association between prefrontal cortex grey matter volume and spatial working memory ability. 41 In the context of the inconsistent associations reported between neuroanatomy and cognitive ability among traditional samples of patients with schizophrenia and BD-I, novel approaches to patient classification based on working memory ability may be usefully applied to studies elucidating neurobiological mechanisms of shared cognitive dysfunctions among (some) individuals with either of these disorders.
The characterization of neuroanatomical features distinguishing patients with cognitive subtypes of psychosis or mood disorders, particularly those defined by working memory profile, may highlight regions of distinct neuropathology for targeted genetic and neurobiological interrogation. The goal of the present study was to quantify the grey and white matter volume differences associated with working memory performance in a pooled sample of patients with schizophrenia, schizoaffective disorder or BD-I. Dichotomous clinical subtypes were defined according to working memory performance accuracy: based on standard working memory task (2-back condition) performance, cross-disorder subtypes for comparison comprised an "executively deficit" (ED) group scoring less than 50% correct and an "executively spared" (ES) group scoring above 50% (i.e., comparable to healthy control performance). We hypothesized that, independent of diagnosis, patients with more severe working memory impairments would show more pronounced deficits of prefrontal grey and white matter volume relative to both healthy controls and to the subgroup of patients with intact cognitive ability.
Methods

Participants
We included participants meeting ICD-10 criteria for schizophrenia or schizoaffective disorder (collectively referred to as the schizophrenia group) or for BD-I; diagnoses were confirmed using the OPCRIT algorithm 42 applied to interviewer ratings on the Diagnostic Interview for Psychosis (DIP). 43 Patients were recruited between 2010 and 2013 from outpatient services of South Eastern Sydney and St. Vincent's Hospital health services and through local community advertisements. Additional participants with schizophrenia were recruited from the Australian Schizophrenia Research Bank (ASRB) volunteer database, 44 and patients with BD-I were recruited from the Black Dog Institute Bipolar Disorders Clinic. 45 We recruited healthy controls from the ASRB database and through advertisement in the local community. Controls were required to have no personal history of DSM-IV Axis 1 disorders and no history of psychosis in their first-degree biological relatives. General exclusion criteria applied to both patients and controls included inability to communicate sufficiently in English, current neurologic disorder, head injuries with loss of consciousness, a diagnosis of substance abuse or dependence in the 6 months preceding the study and/or electroconvulsive therapy within the 6 months preceding the study.
All volunteers provided informed consent according to procedures approved by the University of New South Wales Human Research Ethics committees (HC12384), the South East Sydney and Illawarra Area Health Service (HREC 09/081) and St. Vincent's Hospital Sydney (HREC/10/ SVH/9). In cases where clinical participants were recruited from hospital outpatient units, the ability to provide informed consent was confirmed by the treating medical staff.
Cognitive and clinical assessment
Current symptom severity was assessed in patients using the Positive and Negative Syndrome Scale (PANSS), 46 the DIP 43 and the Global Assessment of Functioning scale. 47 We used DIP items to identify a lifetime history of psychotic symptoms, including hallucinations or delusions. Data on psychiatric medications were collected via self-report and, when further clarification was required, via contact with the participants' treating clinicians. Participants were also assessed using the Edinburgh Handedness Inventory 48 and the Depression, Anxiety and Stress Scale. 49 54 
Working memory subtypes
We administered an n-back task 28 during a functional imaging paradigm to assess working memory ability (see the study by Quidé and colleagues 13 ). Participants were shown a pseudorandomized sequence of numbers (1-4) every 1800 ms and were asked to recall the number presented 2 stimulus trials previously (2-back, presented 3600 ms prior). Accuracy was recorded as percentage correct of the total possible number of responses (incorrect and missed trials). Prior to scanning, patients were trained to achieve at least 50% accuracy on the n-back task. Those who achieved less than 50% accuracy during the task composed the ED group, and those scoring above 50% composed the ES group. The 50% cut-off for distinction of clinical subgroups was used to create a subgroup of participants comparable to the controls, who achieved no lower than 50% accuracy. The number of recruits to the control group who recorded accuracy below the 50% criterion was insufficient to form a control-deficit comparison subgroup, so they were excluded from all analyses.
Image processing
High-resolution T 1 -weighted structural MRI scans (MPRAGE) were collected on a Philips Achieva 3 T scanner with the following parameters: repetition time 8.9 ms, echo time 4.1 ms, field of view 240 mm, matrix 268 × 268, 200 contiguous 0.9 mm sagittal slices. All scans were screened for artifacts and manually reoriented to anterior-posterior commissure orientation. The VBM8 toolbox for SPM8 was used for image analysis (http://dbm.neuro.uni-jena.de/vbm/). We applied a unified segmentation approach combined with hidden Markov random fields to delineate grey and white matter and cerebrospinal fluid segments. Normalization using a nonlinear warp negated the need to further account for total individual brain volume in group-level analyses. Normalized images were additionally modulated with the Jacobian determinants of the deformation parameters, thus preserving the absolute tissue volumes. Finally, images were smoothed with an 8 mm full-width at half-maximum filter for inclusion in group-based analyses.
Statistical analysis
Two analysis approaches were undertaken. The first group of analyses aimed to assess any differences in grey and white matter volume in the schizophrenia and BD-I groups relative both to the control group and to each other. For this approach, we undertook an analysis of variance (ANOVA) to compare images from 3 groups, using age and sex as covariates of no interest. We performed post hoc 2-sample t test analyses to test the significance and directionality of pairwise between-group differences. In a pooled group of all clinical participants (schizophrenia and BD-I), regression analyses explored any effects of medication dose on either grey or white matter volume (imipramine-and chlorpromazine-equivalent doses).
The second set of analyses compared volume differences of grey and white matter among the subtypes defined according to working memory ability relative to the control group and to each other. We performed an ANOVA to compare images from the 3 groups, using age and sex as covariates of no interest, further quantifying between-group differences using post hoc 2-sample t tests. In addition, full factorial analyses were used to examine any statistical interactions between diagnostic groups (control, schizophrenia, BD-I) and perform ance accuracy (score) on the 2-back condition.
Statistical significance in all analyses was inferred at the cluster level with family-wise error correction (FWE) at p < 0.05 (after applying an uncorrected voxel-wise threshold of p < 0.005). This method allows for nonisotropic smoothness in the data, taking into account both the peak height and spatial extent of significant clusters, and is sensitive to the spatial distribution of significant voxels. Regions showing significant differences in grey matter volume between groups were localized using the WFU PickAtlas toolbox for SPM8, incorporating the Montreal Neurological Institute atlas labels (v3.0.3; http://fmri.wfubmc.edu /software/PickAtlas). Statistical analyses of sociodemographic, clinical and cognitive data were conducted using PASW Statistics version 21 (SPSS Inc.). We used 1-way ANOVA with Tukey honestly significant difference post hoc tests, 2-sample t tests, χ 2 analyses and independent-samples median tests, as appropriate, to investigate differences among both clinical and cognitive groups of patients relative to controls (significance threshold for each test was set at α = 0.05).
Results
Sample
We included 40 patients in the schizophrenia group (28 with schizophrenia and 12 with schizoaffective disorder), 30 patients in the BD-I group and 34 participants in the control group. The ED subgroup comprised 32 participants: 10 patients with BD-I and 22 with schizophrenia. The ES subgroup comprised 38 participants: 20 patients with BD-I and 18 with schizophrenia. Tables 1 and 2 report detailed characteristics of the cognitively derived (ED, ES) subgroups. The ED group was significantly older than the control and ES groups (both p < 0.05); there was no difference in age between the control and ES groups. Both patient groups showed significant WASI-IQ impairments compared with controls, but the ES group had a significantly higher IQ than the ED group (p = 0.027). The ED group showed substantially more severe symptoms across all PANSS subdomains, particularly negative symptoms, as well as poorer global functioning than the ES group; however, there was no difference between these 2 groups in the frequency of a lifetime history of psychotic symptoms. There were no differences between the ES and ED groups in frequency or dose of antipsychotic or anti depressant medications, but the ES group received more mood stabilizers (Table 1) .
Comparison of cross-disorder subtypes defined by executive function
Participant characteristics
Whole brain volume differences between cross-disorder subtypes
We observed grey matter volume reductions for each crossdisorder performance subtype (ED, ES) relative to controls (Fig. 1 ). An overall ANOVA (controlling for age and sex) revealed a main effect across the 3 groups (F 2,99 = 10.12, p < 0.001, uncorrected) in the right precuneus and superior parietal (angular) gyrus, right rolandic operculum, left superior and orbital frontal gyri and cerebellar vermis.
Pairwise comparison of patients grouped according to working memory ability showed that, relative to controls, patients in the ED group showed grey matter volume reductions of the bilateral superior, middle, medial frontal and anterior cingulate gyri; right rolandic and inferior opercular gyri; and hippocampus (all p < 0.05, FWE-corrected). In the ES group relative to controls, grey matter volume differences were located in the right precuneus and angular gyrus and in the left superior and medial orbital frontal gyri. Neither the ED nor the ES group showed any regions of increased grey matter volume relative to the control group. Table 3 provides detailed results of these comparisons.
Comparing the patient subgroups directly, the ED group showed grey matter volume reductions relative to the ES group in a large cluster encompassing the right rolandic operculum (inferior frontal), precentral and postcentral gyri (all p < 0.05, FWE-corrected), controlling for age and sex.
Assessment of white matter volume among the 3 groups identified no significant differences in any comparison ( Fig. 1 and Table 3 ). Table 2 outlines detailed participant characteristics according to clinical diagnoses. Both diagnostic groups (schizophrenia, BD-I) were significantly older than the control group, but did not differ from each other (Tukey honestly significant difference test, p = 0.34). There were no differences in sex distribution across groups. Participants with schizophrenia had significantly lower mean WASI-IQ equivalent scores than controls (p < 0.001), whereas those with BD-I showed only a nonsignificant trend toward lower mean WASI-IQ scores relative to controls (p = 0.06; Table 2 ). Compared with patients in the BD-I group, patients in the schizophrenia group had significantly more severe symptoms across all PANSS subdomains, lower global functioning and more frequent lifetime history of psychosis. Most patients (96%) were medicated at the time of scanning; patients with schizophrenia more frequently received antipsychotics, and those with BD-I more frequently received mood stabilizers.
Comparison of traditional diagnostic groups
Participant characteristics
Whole-brain volume differences between clinical groups
Characteristic reductions of grey matter volumes were observed in each disorder relative to controls. An overall ANOVA, including age and sex as covariates, revealed a main effect across 3 groups (F 2,99 = 10.12, p < 0.001, uncorrected) in the right precuneus, left superior orbital frontal gyrus, parahippocampus and cerebellar vermis.
We assessed directionality of effect using post-hoc t tests; after controlling for age and sex, we inferred significant whole brain differences at the cluster level with FWE correction (p < 0.05). Full details of the 2-sample comparisons are reported in Table 4 . Relative to controls, patients with schizophrenia showed significant reductions of grey matter volume in the left hippocampus and parahippocampus; left medial, superior and middle orbital frontal gyri; and right middle frontal gyrus. Relative to controls, patients with BD-I showed robust grey matter volume reductions in the right precuneus and superior parietal (angular) and postcentral gyri and the left superior and medial orbital frontal gyri (Fig. 2) . Neither clinical group showed any regions of increased grey matter volume relative to the control group that survived correction for multiple comparisons. Direct comparison of the schizophrenia and BD-I groups revealed no regional clusters surviving the significance threshold. Additional analysis identified no regional interaction between clin ical group and n-back performance score. Within the pooled clinical group, we found no significant associations between grey matter volume and mean doses of antipsychotics (chlorpromazine equivalents) or antidepressants (imipramine equiva lents). Assessment of white matter volume among the 3 groups revealed no differences in any comparison.
In addition, we identified no significant associations between white matter volume and doses of imipramine or chlorpromazine equivalents (Fig. 2 and Table 4 ).
Discussion
This study provides evidence for distinct neuroanatomical profiles differentiating cross-disorder subtypes of patients (with schizophrenia or BD-I) who show pronounced working memory deficits from their nondeficit counterparts. To our knowledge, these results are among the first to demonstrate the utility of the Research Domain Criteria project (RDoC) 6 approach to identifying shared intermediate phenotypes across the psychosis-mood diagnostic spectrum. In a subgroup of individuals characterized by severe impairments in working memory (regardless of diagnosis), diffuse grey matter volume reductions of the right anterior cingulate; superior, middle and 
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inferior frontal gyri; and left hippocampus were revealed relative to healthy controls. In contrast, the group of patients with relatively spared working memory performance showed more circumscribed grey matter volumne loss within the left orbital frontal gyri and the right precuneus. Notably, the pattern of neuroanatomical aberrations for the group with relatively spared working memory performance overlapped with volume reductions in the BD-I group (in traditional diagnostic comparisons); however, it is notable that patients with schizophrenia made up almost half the ES subgroup. Direct comparison of the ES and ED subgroups showed substantial reductions of grey matter volume in the ED group localized around the right rolandic operculum (right inferior frontal gyrus; rIFG) and pre-and postcentral gyri, with clusters extending toward the insular cortex. Surprisingly, there were no significant differences in white matter volume among the ES or ED groups relative to controls. The lack of white matter volume differences may represent an issue of insufficient power, but in the context of significant grey matter volume findings, these results imply greater severity of, or less interindividual variability in, grey matter volume aberrations in patients with subtypes of psychosis and mood disorders characterized by working memory impairment. The patients with greater impairments in working memory ability may thus represent a neuroanatomically distinct subtype that spans traditional diagnostic categories of schizophrenia-spectrum disorders and BD-I. These results were revealed in the context of a lack of grey matter volume differences between the traditional diagnostic categories of BD-I and schizophrenia (including schizoaffective disorder). Substantial evidence has highlighted common brain aberrations, including both global and regional deficits, 10, 12, 29, 30 in addition to selected diagnosis-specific findings 9,11 among patients with these disorders relative to controls. However, the regions identified as "distinguishing" the diagnoses vary across studies, and our results appear consistent with those of recent investigations demonstrating a lack of substantial diagnostic specificity in neuroanatomical profile. 12, 55 This variability across studies may be attributable, in part, to variation in the significance thresholds applied, statistical power, or to many other factors intrinsic to the acquisition or analysis techniques involved. However, the variability is likely also a consequence of the inherent variability across and within patient samples, which hampers the generalizability of any imaging analyses according to traditional diagnostic categories.
While our analytic approach represents an attempt to reduce the phenotypic heterogeneity inherent in traditional diagnostic categories of schizophrenia and BD, we cannot presume to have attenuated all within-group variability with the use of cognitively derived subtypes. However, the utility of this approach is in delineating a cross-disorder subgroup of patients with severe working memory deficit and characterized by extensive grey matter volume loss in frontal cortices and hippocampal regions, greater functional impairment and more severe symptomatology. The distribution of the cognitive phenotype across disorders is consistent with previous evidence of more severe working memory deficits in patients with schizophrenia 8 and suggests that these cross-disorder cases with severe cognitive deficit may share some genetic underpinnings. This proposal is supported by evidence that many of the shared risk genotypes (notably evident only in subsets of both schizophrenia and BD-I populations), have been shown to modulate neurocognitive functioning and brain morphometry in clinical and nonclinical populations. For example, multiple polymorphisms within the catechol-Omethyl transferase (COMT) and disrupted in schizophrenia (DISC1) genes have been associated with differential cognitive ability in people with both disorders [56] [57] [58] across a range of domains, including n-back performance, 19 as well as modulating cortical [58] [59] [60] and subcortical 61, 62 brain volumes. The complex phenotypes of these cognitively derived subgroups imply potential for multiple genes of small effect to confer susceptibility collectively, both to cognitive capacity and illness risk. 63 The specific finding of more pronounced rIFG volume loss in the ED group is consistent with findings of previous structural and functional imaging studies of working memory function; 64, 65 however, differential rIFG volume might also be more broadly relevant for modulating global cognitive and clinical features. In the current analysis, the ED subgroup demonstrated significant impairments across multiple cognitive measures, including general intelligence (IQ), immediate and delayed memory, language, attention and global functioning (Table 1) . Previous evidence supports the association between volume of the inferior frontal regions and the regulation of cognitive control, attention and salience detection; 66, 67 notably, rIFG lesions are associated with impairments in cognitive control, 68 while positive associations between IFG morphometry and verbal cognitive function have also been reported in patients with psychosis 69 and healthy controls. 65 Complementary findings from functional imaging studies have frequently reported that heightened IFG activation during working memory tasks may reflect compensatory mechanisms among highfunctioning patients performing the task equivalently to controls. 70, 71 The specific rIFG volume loss observed here may also contribute to the differential clinical profiles of these cross-disorder subtypes, as the ED patients demonstrate greater symptom severity across all domains of positive, negative and general symptoms and poorer global functioning. Previous studies have found associations between rIFG volume and severity of both positive [72] [73] [74] and negative symptoms, 75 while a recent meta-analysis also identified that rIFG volume may differentiate high-risk individuals who transition to psychosis from those who do not transition. 76 Notably, an association has been reported between increasing age and reduced volume of the rIFG and superior temporal gyrus in a subsample of patients with schizophrenia who have prominent symptoms of paranoia. 77 This may have particular relevance to growing literature documenting an apparent "accelerated" aging trajectory in several psychotic and mood disorders. 78, 79 Despite a statistical control for age in all analyses, it is possible that the significant age differences among the groups in the present study may also contribute to the observed results.
Limitations
Limitations of the present study include those inherent to structural imaging studies, particularly those using the voxel-based analysis technique, which relies on predominantly automated segmentation and labelling to identify key regions of significant group difference. Voxel-based analyses are useful as they provide an unbiased, whole brain comparison, but they are susceptible to normalization error and misregistration, 80 also limiting the accuracy of regional localization with relatively coarse atlas labelling. However, the present data analysis involved a non linear warp, which reduces reliance on global brain shape during registration and increases registration accuracy. In addition, these novel findings should be considered with caution given the relatively small size of the patient groups, who were recruited predominantly from outpatient sources. Future studies of larger samples, including inpatients, will be required to determine the generalizability of the present results. A further limitation lies in the restriction of included controls to only those whose performance exceeded the criterion of greater than 50% accuracy. This restriction was under taken to ensure comparable performance accuracy between the ES and control groups. The small number of controls that exhibited poorer working memory function (n = 8, excluded from all analyses) was deemed insufficient to permit examination of an additional, control-deficit, comparison group.
In addition, these analyses have not assessed associations of brain volume with dosages of mood stabilizer medications, which were more frequently prescribed for the BD-I group (Table 2 ). All analyses have assessed the effects of both imipramine and chlorpromazine equivalent standardized doses on grey and white matter volumes; however, an equiva lent standardized dose index is not available for mood stabil izers. Our participants were receiving a variety of agents, including lithium, valproate, carbamazepine and lamotrigine; lithium in particular has been associated previously with increased subcortical volume. 81 However, in the present analysis, none of the clinical groups showed any significant increases of grey matter volume relative to the control group. Furthermore, a meta-analysis comparing treated and untreated first-episode patients with schizophrenia 82 has suggested an effect of antipsychotic treatments on the grey matter volume of regions including the insula, medial and inferior frontal cortices, superior temporal gyrus, amygdala and precentral gyrus. In the present study, direct investigation of any correlative associations between imipramine and chlorpromazine mean doses and brain volumes did not identify significant associations. Importantly, the cognitively defined subgroups showed no differences in the frequency or dose of antipsychotics or anti depressants (Table 1) .
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Conclusion
The present findings of more pronounced volume loss in frontal cortices and hippocampal regions in a cross-disorder subtype of patients defined by severe working memory impairment, in concert with their greater functional disability and more severe symptomatology, highlights the utility of considering working memory ability as a "shared" intermediate phenotype for some patients with schizophrenia and BD-I. We have demonstrated neuroanatomical commonalities among patients with schizophrenia and BD-I with pronounced working memory deficits, while patients with spared working memory capacity showed less severe grey matter loss relative to controls; aberrations of rIFG volume may mediate some of the phenotypic differences among cognitively derived subtypes that span the traditional diagnostic categories of schizophrenia and BD.
